COVID-19 Spike Protein Variants and Their Potential for Increased Lethality: A Comprehensive Review

AbstractSince the emergence of Coronavirus Disease 2019 (COVID-19) in late 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has continuously evolved through genetic mutations. Many of these mutations have occurred in the viral spike (S) protein, the primary structure responsible for host-cell attachment and entry. Several variants have demonstrated enhanced transmissibility, immune escape, and altered pathogenicity. This review examines major spike protein variants that have emerged during the pandemic, their molecular characteristics, and evidence regarding increased virulence and lethality. Understanding these evolutionary changes is essential for improving surveillance systems, vaccine development, and pandemic preparedness.Keywords: COVID-19, SARS-CoV-2, spike protein, variants, virulence, lethality, mutations, pandemic preparednessIntroductionThe COVID-19 pandemic has caused unprecedented global health, social, and economic disruption. SARS-CoV-2, an RNA virus belonging to the Coronaviridae family, possesses a spike glycoprotein that mediates binding to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells (Hoffmann et al., 2020). Due to replication errors and selective pressures, the virus has accumulated mutations, leading to the emergence of multiple variants with distinct biological properties (Harvey et al., 2021).The spike protein remains the most critical target for vaccines and neutralizing antibodies. Consequently, mutations within this protein can significantly affect viral fitness, transmissibility, immune evasion, and disease severity.Structure and Function of the Spike ProteinThe spike protein consists of two functional subunits:·S1 subunit: Contains the receptor-binding domain (RBD).·S2 subunit: Facilitates membrane fusion and viral entry.Mutations in the RBD can alter receptor affinity, while changes near the furin cleavage site may enhance infectivity and pathogenicity (Walls et al., 2020).Major Spike Protein VariantsAlpha Variant (B.1.1.7)The Alpha variant was first identified in the United Kingdom in late 2020. Key spike mutations included:·N501Y·P681H·Δ69-70 deletionThe N501Y mutation increased ACE2 receptor binding affinity, contributing to enhanced transmission. Epidemiological studies suggested a higher mortality risk compared to earlier strains (Davies et al., 2021).Beta Variant (B.1.351)Initially detected in South Africa, Beta contained:·K417N·E484K·N501YThese mutations significantly reduced neutralization by antibodies generated through previous infection or vaccination (Tegally et al., 2021).Gamma Variant (P.1)First reported in Brazil, Gamma shared several mutations with Beta, particularly E484K and N501Y, resulting in increased immune escape and reinfection potential (Faria et al., 2021).Delta Variant (B.1.617.2)The Delta variant emerged in India and rapidly became dominant worldwide.Notable spike mutations included:·L452R·T478K·P681RDelta exhibited substantially higher transmissibility and was associated with increased hospitalization and mortality rates compared with Alpha (Twohig et al., 2022). Enhanced replication efficiency and elevated viral loads contributed to its greater pathogenicity.Omicron Variant (B.1.1.529)Omicron carried more than 30 spike protein mutations, including:·N501Y·K417N·T478K·E484AAlthough Omicron demonstrated exceptional transmissibility and immune evasion, its intrinsic severity was generally lower than Delta in vaccinated populations (Viana et al., 2022). However, its extensive spread still resulted in substantial numbers of hospitalizations and deaths globally.Spike Protein Mutations Associated with Increased VirulenceN501YThis mutation increases spike protein affinity for the ACE2 receptor, facilitating viral entry and transmission (Starr et al., 2020).L452RL452R enhances receptor binding and contributes to immune escape, making variants such as Delta more difficult to neutralize (Motozono et al., 2021).E484KKnown as an "escape mutation," E484K reduces neutralization by antibodies and has been implicated in reinfections (Greaney et al., 2021).P681R and P681HThese mutations occur near the furin cleavage site and improve viral entry into host cells, potentially increasing infectivity and disease severity (Saito et al., 2022).Could Future Spike Variants Become More Lethal?Viral evolution does not necessarily favor increased lethality. Instead, natural selection often promotes enhanced transmission. Nevertheless, more lethal variants can emerge if mutations simultaneously improve transmission and pathogenicity.Several factors may contribute to future high-risk variants:1.Increased ACE2 binding affinity.2.Enhanced immune evasion.3.Improved replication efficiency.4.Expanded tissue tropism.5.Recombination between circulating variants.The emergence of recombinant variants demonstrates that SARS-CoV-2 continues to evolve in unpredictable ways (Jackson et al., 2022).Implications for Vaccine DevelopmentThe continuous evolution of spike protein variants presents challenges for vaccine effectiveness. Updated vaccine formulations targeting circulating variants can improve protection against severe disease. Future vaccine strategies may focus on:·Universal coronavirus vaccines.·Conserved epitope targeting.·Multivalent vaccine platforms.·Mucosal immunity enhancement.Public Health Surveillance and PreparednessGenomic surveillance remains critical for identifying potentially dangerous variants before widespread transmission occurs. Integration of genomic sequencing, epidemiological monitoring, and artificial intelligence-based prediction systems can strengthen preparedness against future outbreaks.Future Research DirectionsFuture studies should focus on:·Predicting high-risk spike mutations.·Understanding mutation combinations that increase virulence.·Developing broad-spectrum antiviral therapies.·Investigating long-term evolutionary trajectories of SARS-CoV-2.ConclusionThe SARS-CoV-2 spike protein remains the principal driver of viral evolution and adaptation. Variants such as Alpha, Beta, Gamma, Delta, and Omicron have demonstrated how mutations can alter transmissibility, immune escape, and disease severity. While Delta showed evidence of increased lethality compared with earlier variants, future evolutionary pathways remain uncertain. Continuous genomic surveillance, vaccine adaptation, and global collaboration are essential to mitigate risks posed by emerging spike protein variants.References